Lenvatinib after liver cancer surgery to prevent recurrence
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether taking lenvatinib after liver cancer surgery can lower the chance of the cancer coming back. It is for people who have a high risk of recurrence and have recently had their liver tumor completely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You had surgery to remove your liver cancer 4 to 8 weeks ago, and doctors confirmed no cancer cells were left behind.
- Your cancer is only in the liver and has not spread to blood vessels or other organs.
- You have at least one high-risk factor: tumor larger than 5 cm, more than 3 tumors, signs of blood vessel invasion, or certain tumor grades.
- Your liver and kidney function, blood counts, and clotting are within safe limits as checked by recent tests.
- You are willing to use reliable birth control during the study and for 60 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two targeted therapy drugs, lenvatinib or regorafenib, for people with advanced liver cancer that got worse after first treatment with immunotherapy. It aims to see if these drugs can help when immunotherapy stops working.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This early-phase study tests whether adding medicines to ablation (heating/freezing to destroy liver tumors) can keep liver cancer from coming back. It’s for people whose liver cancer recurred after prior surgery/ablation but still fits specific criteria, with the goal of improving disease control.
This trial tests whether a combination of two drugs, QL1706 (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks blood supply to tumors), given before surgery can help shrink liver cancer and lower the chance of it coming back. It may be an option for people with certain types of liver cancer that are considered high-risk for recurrence.
This trial tests a targeted therapy (lenvatinib) given after a living-donor liver transplant to prevent high-risk liver cancer from coming back. It is for people whose cancer is aggressive or did not respond well to previous treatments.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.